Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Sunday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Down 0.9 %

Enzo Biochem stock opened at $0.65 on Friday. The company has a fifty day simple moving average of $0.84 and a 200-day simple moving average of $1.03. Enzo Biochem has a 52-week low of $0.63 and a 52-week high of $1.40.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Enzo Biochem Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 15th were paid a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 61.35%. The ex-dividend date of this dividend was Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

A number of hedge funds have recently modified their holdings of ENZ. Renaissance Technologies LLC boosted its holdings in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. BBR Partners LLC acquired a new position in Enzo Biochem in the third quarter valued at approximately $112,000. Finally, XTX Topco Ltd grew its position in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.